Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2021-08-11 00:00:00 ET · period of report 2021-08-09 · accession 0001213900-21-041711 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-08-11 | 2021-08-09 | ORMP | KIDRON NADAV | Pres, CEO, Dir, 10% | S - Sale | $20.11 | -220.0K | 648.6K | -25% | -$4.42M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-09 | S | D | 220,000 | $20.11 | 648,573 | D | — | — | (F1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $21.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range. |